Skip to content
MarketScale
‹ Back to Industries

Sciences

U.S. Department of Energy Unveils New Lithium-Sulfur Battery Component

Researchers at the U.S. Department of Energy’s Berkeley Lab reported that a new, lithium-sulfur battery component can hold double the capacity then that a conventional lithium sulfur battery. According to a press release from Berkeley Lab, when a lithium-sulfur battery stores and releases energy, the chemical reaction produces mobile molecules of sulfur that become disconnected…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences ·
Share
U.S. Department of Energy Unveils New Lithium-Sulfur Battery Component

Key takeaways

01

Department of Energy’s Berkeley Lab reported that a new, lithium-sulfur battery component can hold double the capacity then that a conventional lithium sulfur battery.

02

According to a press release from Berkeley Lab, when a lithium-sulfur battery stores and releases energy, the chemical reaction produces mobile molecules of sulfur that become disconnected…

Researchers at the U.S. Department of Energy’s Berkeley Lab reported that a new, lithium-sulfur battery component can hold double the capacity then that a conventional lithium sulfur battery.

According to a press release from Berkeley Lab, when a lithium-sulfur battery stores and releases energy, the chemical reaction produces mobile molecules of sulfur that become disconnected from the electrode, causing it to degrade and ultimately lowering the battery’s capacity over time. The new component, however yields more of a charge after 100+ charge cycles, which is a key component in the metrics of electric vehicles and aviation vehicles. The addition of a newly designed polymer binder, allows regulation of key ion transport processes.

We can now reliably and efficiently model sulfur chemistry within these binders based on learning from detailed quantum mechanical simulations of the dissolved sulfur-containing products,” says David Prendergast, director at Foundry’s Theory Facility.

This new polymer advances the power of lithium-sulfur batteries, and is the next step for more energy efficient, electric vehicles.

To read more of this new battery technology, check out the full news release.

About the author

S
Sciences

New to MarketScale?

MarketScale is the platform Sciences companies use to turn their own experts into content like this. Want the short overview?

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences